Patent to Pfizer could delay Indian vaccines for pneumonia

With global pharmaceutical giant Pfizer getting a patent last month for its pneumonia vaccine, Indian companies’ plans to introduce cheaper products could get delayed.

Pneumonia kills 200,000 children in India everyyear. The vaccineisavailableintheprivate market from two global pharma giants, Pfizer and GlaxoSmithKline (GSK). Pfizer’s vaccine, called PCV13 and marketed as Prevnar13, provides protection against13strainsofthethestreptococcus pneumoniae bacteria. GSK’s product can provide protection against 10 strains.

Four Indian companies — Serum Institute, Panacea Biotec, Biological E and Tergene Biotech — have pneumococcal conjugate vaccine (PCV) products in the pipeline, according to SathguruManagement Consultant, which had earlier this year made a report on the Indian vaccine market for the Confederation of Indian Industry (CII). Pneumonia kills 200,000 children in India every year Pfizer’s pneumonia vaccine was included in the Universal Immunisation Programme in May Gavi, the global vaccine

“Pfizer’s patent doesn’t cover a mechanism of action and is primarily on formulation of the product. All the four Indian companies with PCV candidates in the pipeline have different formulations and if any of them infringe any part of the granted alliance, to support vaccine under UIP for three years In August, the pneumonia vaccine got patent Pfizer’s PCV13, marketed as Prevnar13, costs ~11,400 for 3 doses patent, there could be a delay in launch of the product due to time for reformulation to ensure freedom to operate,” says Pushpa Vijayaraghavan, director of Sathguru. The patent office at Delhi granted one to Pfizer’s PCV, which has been in the market for 10 years. It is priced ~11,400 for three doses. The vaccine also got introduced in the UniversalImmunisationProgramme (UIP) of the government in May in a phased manner, with the assistance of Gavi, the global vaccine alliance. It is currently implemented in three states. The alliance will be making these Pfizer vaccines available in India only for three years, following which government will have to buy it on its own.

“The implication could be potential delays and is unlikely to a complete commercialisation threat to any of the Indian candidates,” says Vijayaraghavan. While Serum Institute and Panacea Biotec did not respond to e-mail queries, Biological E and Tergene Biotech could not be reached.

With demand for PCV increasing, GSK also aims to expand the market. "We have shown our interest to the government as it has chosen another brand for the rollout of pneumococcal vaccine under UIP. Our products are already used in many of our neighbouring countries as part of their national immunisation program. Once our brand is accepted for UIP, our vaccine volume will increase,” says A Vaidheesh, managing director for GSK in India.

Sathguru estimates the Indianvaccine industry would grow to $3.1-3.3 billion by 2020, from $1-1.2 billion in 2015. This covers the domestic UIP, private channel and export markets. This would also include rapid growth for the private market, dominated by multinationals. This market is expected to grow to $1.9 billion by 2020 from $265 million in 2015, largely with PCV.

“Our business strategy continues to focus on growing our core pneumococcal business, through increasing access and awareness and enhancing the product portfolio,” said a spokesperson at Pfizer. “We also hope to partner in the scale-up of the public immunisation program. There are several vaccines such as PCV, HPV (Human Papilloma Virus), varicella (chicken pox) and Hepatitis A, that are only sold by multinationals in India, not made by Indian companies. They derive strength from their global research and development expertise and differentiated portfolio, and have often leveraged marketing partnerships with Indian pharma companies to gain market share.

French pharma giant Sanofi has a tenth of its global vaccine workforce in this country. With over a dozen wide-ranging vaccines in its portfolio, Sanofi Pasteur, its vaccine division, is amongst the top three vaccine companies in India and has a private market share of 11 per cent, according to IMS Health this June.